![origenis_logo_Pantone [Konvertiert]_2020](https://static.wixstatic.com/media/9afeac_83ea95f8f63144538d48a310b96d7f33~mv2.png/v1/fill/w_260,h_53,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/origenis_logo_Pantone%20%5BKonvertiert%5D_2020.png){kind=logo}
London, UK – OncoBone Ventures Ltd, based in the UK, and Origenis GmbH, headquartered in Planegg, Germany, have signed a Framework Agreement to develop novel therapies targeJng cancer bone metastasis, addressing a significant unmet medical need. Currently, there are no effecJve treatments for bone metastases, which affect 70-90% of advanced breast and prostate cancer paJents, with less than 5% surviving beyond five years post-diagnosis.
top of page
bottom of page
Comments